|
1
|
Durie BG: Role of new treatment approaches
in defining treatment goals in multiple myeloma - the ultimate goal
is extended survival. Cancer Treat Rev. 36:S18–S23. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shain KH and Dalton WS:
Environmental-mediated drug resistance: a target for multiple
myeloma therapy. Expert Rev Hematol. 2:649–662. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rajkumar SV: Treatment of multiple
myeloma. Nat Rev Clin Oncol. 8:479–491. 2011. View Article : Google Scholar
|
|
4
|
Mohindru M and Verma A: Engineered
antibodies act as targeted therapies in cancer treatment. Indian J
Pediatr. 72:943–947. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Binyamin L, Borghaei H and Weiner LM:
Cancer therapy with engineered monoclonal antibodies. Update on
cancer therapeutics. 1:147–157. 2006. View Article : Google Scholar
|
|
6
|
Pastan I: Immunotoxins containing
Pseudomonas exotoxin A: a short history. Cancer Immunol
Immunother. 52:338–341. 2003.PubMed/NCBI
|
|
7
|
Kreitman RJ: Recombinant immunotoxins
containing truncated bacterial toxins for the treatment of
hematologic malignancies. BioDrugs. 23:1–13. 2009. View Article : Google Scholar
|
|
8
|
Li J and Zhang JK: LHRH-PE40-induced
vascular leak syndrome. Toxicol Mech Methods. 16:473–476. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li J, Sun Y and Zhang J: A recombinant
protein LHRH-PE40 for tumour therapy: preclinical safety studies.
Basic Clin Pharmacol Toxicol. 99:398–404. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kreitman RJ: Recombinant immunotoxins for
the treatment of chemoresistant hematologic malignancies. Curr
Pharm Des. 15:2652–2664. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Siegall CB, Chaudhary VK, FitzGerald DJ
and Pastan I: Cytotoxic activity of an interleukin
6-Pseudomonas exotoxin fusion protein on human myeloma
cells. Proc Natl Acad Sci USA. 85:9738–9742. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kreitman RJ, Siegall CB, FitzGerald DJ,
Epstein J, Barlogie B and Pastan I: Interleukin-6 fused to a mutant
form of Pseudomonas exotoxin kills malignant cells from
patients with multiple myeloma. Blood. 79:1775–1780.
1992.PubMed/NCBI
|
|
13
|
Siegall CB, Schwab G, Nordan RP,
FitzGerald DJ and Pastan I: Expression of the interleukin 6
receptor and interleukin 6 in prostate carcinoma cells. Cancer Res.
50:7786–7788. 1990.PubMed/NCBI
|
|
14
|
Siegall CB, FitzGerald DJ and Pastan I:
Cytotoxicity of IL6-PE40 and derivatives on tumor cells expressing
a range of interleukin 6 receptor levels. J Biol Chem.
265:16318–16323. 1990.PubMed/NCBI
|
|
15
|
Simpson RJ, Hammacher A, Smith DK,
Matthews JM and Ward LD: Interleukin-6: structure-function
relationships. Protein Sci. 6:929–955. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hong DS, Angelo LS and Kurzrock R:
Interleukin-6 and its receptor in cancer: implications for
translational therapeutics. Cancer. 110:1911–1928. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Siegall CB, Kreitman RJ, FitzGerald DJ and
Pastan I: Antitumor effects of interleukin 6-Pseudomonas
exotoxin chimeric molecules against the human hepatocellular
carcinoma, PLC/PRF/5 in mice. Cancer Res. 51:2831–2836.
1991.PubMed/NCBI
|
|
18
|
Rozemuller H, Rombouts WJ, Touw IP, et al:
Treatment of acute myelocytic leukemia with interleukin-6
Pseudomonas exotoxin fusion protein in a rat leukemia model.
Leukemia. 10:1796–1803. 1996.PubMed/NCBI
|
|
19
|
Proudfoot AE, Brown SC, Bernard AR,
Bonnefoy JY and Kawashima EH: Recombinant human IL-6 expressed in
E. coli undergoes selective N-terminal degradation: evidence
that the protein consists of a stable core and a nonessential
flexible N-terminal. J Protein Chem. 12:489–497. 1993.PubMed/NCBI
|
|
20
|
Hammacher A, Ward LD, Weinstock J,
Treutlein H, Yasukawa K and Simpson RJ: Structure-function analysis
of human IL-6: identification of two distinct regions that are
important for receptor binding. Protein Sci. 3:2280–2293. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ehlers M, Grötzinger J, deHon FD, et al:
Identification of two novel regions of human IL-6 responsible for
receptor binding and signal transduction. J Immunol. 153:1744–1753.
1994.PubMed/NCBI
|
|
22
|
Weldon JE and Pastan I: A guide to taming
a toxin - recombinant immunotoxins constructed from
Pseudomonas exotoxin A for the treatment of cancer. FEBS J.
278:4683–4700. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kreitman RJ and Pastan I: Importance of
the glutamate residue of KDEL in increasing the cytotoxicity of
Pseudomonas exotoxin derivatives and for increased binding
to the KDEL receptor. Biochem J. 307(Pt 1): 29–37. 1995.PubMed/NCBI
|
|
24
|
Grote A, Hiller K, Scheer M, et al: JCat:
a novel tool to adapt codon usage of a target gene to its potential
expression host. Nucleic Acids Res. 33:W526–531. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Brinkmann U, Pai LH, FitzGerald DJ,
Willingham M and Pastan I: B3(Fv)-PE38KDEL, a single-chain
immunotoxin that causes complete regression of a human carcinoma in
mice. Proc Natl Acad Sci USA. 88:8616–8620. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kreitman RJ and Pastan I: Purification and
characterization of IL6-PE4E, a recombinant fusion of interleukin 6
with Pseudomonas exotoxin. Bioconjug Chem. 4:581–585. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Olson BJ and Markwell J: Assays for
determination of protein concentration. Curr Protoc Protein Sci.
Chapter 3(Unit 3): 42007.PubMed/NCBI
|
|
28
|
Tsuchiya M, Takaoka A, Tokioka N and
Matsuura S: Development of an endotoxin-specific Limulus amebocyte
lysate test blocking beta-glucan-mediated pathway by
carboxymethylated curdlan and its application. Nihon Saikingaku
Zasshi. 45:903–911. 1990.(In Japanese).
|
|
29
|
Malich G, Markovic B and Winder C: The
sensitivity and specificity of the MTS tetrazolium assay for
detecting the in vitro cytotoxicity of 20 chemicals using human
cell lines. Toxicology. 124:179–192. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Croucher PI, Shipman CM, Lippitt J, et al:
Osteoprotegerin inhibits the development of osteolytic bone disease
in multiple myeloma. Blood. 98:3534–3540. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Burgess-Brown NA, Sharma S, Sobott F,
Loenarz C, Oppermann U and Gileadi O: Codon optimization can
improve expression of human genes in Escherichia coli: A
multi-gene study. Protein Expr Purif. 59:94–102. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wu X, Jornvall H, Berndt KD and Oppermann
U: Codon optimization reveals critical factors for high level
expression of two rare codon genes in Escherichia coli: RNA
stability and secondary structure but not tRNA abundance. Biochem
Biophys Res Commun. 313:89–96. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kreitman RJ and Pastan I: Immunobiological
treatments of hairy-cell leukaemia. Best Pract Res Clin Haematol.
16:117–133. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pastan I, Hassan R, Fitzgerald DJ and
Kreitman RJ: Immunotoxin therapy of cancer. Nat Rev Cancer.
6:559–565. 2006. View Article : Google Scholar
|
|
35
|
Pastan I, Beers R and Bera TK: Recombinant
immunotoxins in the treatment of cancer. Methods Mol Biol.
248:503–518. 2004.
|
|
36
|
Chiron MF, Fryling CM and FitzGerald D:
Furin-mediated cleavage of Pseudomonas exotoxin-derived
chimeric toxins. J Biol Chem. 272:31707–31711. 1997.PubMed/NCBI
|
|
37
|
Bassi DE, Lopez De Cicco R, Mahloogi H,
Zucker S, Thomas G and Klein-Szanto AJ: Furin inhibition results in
absent or decreased invasiveness and tumorigenicity of human cancer
cells. Proc Natl Acad Sci USA. 98:10326–10331. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Thomas G: Furin at the cutting edge: from
protein traffic to embryogenesis and disease. Nat Rev Mol Cell
Biol. 3:753–766. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bassi DE, Fu J, Lopez de Cicco R and
Klein-Szanto AJ: Proprotein convertases: ‘master switches’ in the
regulation of tumor growth and progression. Mol Carcinog.
44:151–161. 2005.
|
|
40
|
Alberti L, Bachelot T, Duc A, Biota C and
Blay JY: A spliced isoform of interleukin 6 mRNA produced by renal
cell carcinoma encodes for an interleukin 6 inhibitor. Cancer Res.
65:2–5. 2005.PubMed/NCBI
|
|
41
|
Scheller J and Rose-John S: Interleukin-6
and its receptor: from bench to bedside. Med Microbiol Immunol.
195:173–183. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wong VW, Yu J, Cheng AS, et al: High serum
interleukin-6 level predicts future hepatocellular carcinoma
development in patients with chronic hepatitis B. Int J Cancer.
124:2766–2770. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hodge DR, Hurt EM and Farrar WL: The role
of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer.
41:2502–2512. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Song S, Xue J, Fan K, et al: Preparation
and characterization of fusion protein truncated Pseudomonas
Exotoxin A (PE38KDEL) in Escherichia coli. Protein Expr
Purif. 44:52–57. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Nesbitt JE and Fuller GM: Dynamics of
interleukin-6 internalization and degradation in rat hepatocytes. J
Biol Chem. 267:5739–5742. 1992.PubMed/NCBI
|
|
46
|
Lorberboum-Galski H, Garsia RJ, Gately M,
et al: IL2- PE664Glu, a new chimeric protein cytotoxic to
human-activated T lymphocytes. J Biol Chem. 265:16311–16317.
1990.PubMed/NCBI
|
|
47
|
Mori K, Fujimoto-Ouchi K, Onuma E, et al:
Novel models of cancer-related anemia in mice inoculated with
IL-6-producing tumor cells. Biomed Res. 30:47–51. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Jongen-Lavrencic M, Peeters HR, Rozemuller
H, et al: IL-6-induced anaemia in rats: possible pathogenetic
implications for anemia observed in chronic inflammations. Clin Exp
Immunol. 103:328–334. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Raj DS: Role of interleukin-6 in the
anemia of chronic disease. Semin Arthritis Rheum. 38:382–388. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wierzbowska A, Urbanska-Rys H and Robak T:
Circulating IL-6-type cytokines and sIL-6R in patients with
multiple myeloma. Br J Haematol. 105:412–419. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Usnarska-Zubkiewicz L: Level of
interleukin-6 (IL-6), soluble interleukin-6 receptors (sIL-6R) and
tumor necrosis factor alpha (TNF-alpha) in untreated and
progressing multiple myeloma. Pol Arch Med Wewn. 99:30–37. 1998.(In
Polish).
|
|
52
|
Tsutsumi Y, Onda M, Nagata S, Lee B,
Kreitman RJ and Pastan I: Site-specific chemical modification with
polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38
(LMB-2) improves antitumor activity and reduces animal toxicity and
immunogenicity. Proc Natl Acad Sci USA. 97:8548–8553. 2000.
View Article : Google Scholar
|
